In this article
- Overview of PD-1 Immune Checkpoint Inhibitors in B-Cell Lymphoma Treatment
- PD-1 Inhibitors Demonstrate High Response Rates in Classic Hodgkin Lymphoma"
- Clinical Trial Results of PD-1 Inhibitors Across B-Cell Non-Hodgkin Lymphoma Subtypes
- Mechanisms and Future Strategies for PD-1 Inhibitor Immunotherapy
- How CancerFax Helps
A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blood-2017-07-740993.
PD-1 immune checkpoint inhibitor treatment has shown significant efficacy in the treatment of advanced tumors including hematological malignancies. This review focuses on the clinical trials of PD-1 / PD-L1 expression and PD-1 inhibitor immunotherapy for B-cell lymphoma.
Relapsed and refractory classic Hodgkin lymphoma usually have PD-1 positive tumor infiltrating T cells, 9p24 gene changes and high PD-L expression. In Phase I / II clinical trials, PD-1 inhibitors alone can bring an objective response rate (ORR) of 65% to 87% and continuous disease control. The median duration of remission in a phase II clinical trial was 16 months.
In a phase I clinical trial, nivolumab was used to treat relapsed and refractory B-cell non-Hodgkin's lymphoma including follicular lymphoma (CD4 positive T cells in the tumor usually have a large amount of PD-1 expression) and diffuse large B cell lymphoma Tumors (also express PD-1 and PD-L1 to varying degrees). Primary mediastinal large B-cell lymphoma often has 9p24 changes. In a phase II clinical trial, the ORR of pembrolizumab was 35%, the ORR of pembrolizumab was 0, and the treatment was Richter transformation. The ORR of chronic lymphocytic leukemia is 44%. Marginal zone lymphoma also has PD-1 expression, but mantle cell lymphoma does not.
The review also describes the mechanism of PD-1 inhibitor immunotherapy, toxic reactions, predictive markers and combination treatment strategies.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.